Evaluating the impact of recombinant porcine factor VIII compared with activated recombinant factor VII on acquired hemophilia A outcomes

Objective: To compare mortality and readmission rates for patients with acquired hemophilia A (AHA) who were observed to use activated recombinant factor VII (rFVIIa) and/or recombinant porcine factor VIII (rpFVIII) during a hospital admission. Methods: The Medicare Limited Data Set was used for this analysis. Patients were selected into the study if they had a diagnosis of AHA and were treated with rpFVIII and/or rFVIIa between 1 January 2015 and 31 December 2019, among other criteria. Results: The probability of death or readmission with treatment within 12 months of a previous treatment was 40% lower in rpFVIII cases than rFVIIa cases (p = 0.047). Conclusion: Patients with AHA who received treatment with rpFVIII experienced significant declines in mortality and readmissions compared with patients treated with rFVIIa.